Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Trastuzumab deruxtecan
Other

Trastuzumab deruxtecan

Tracked across 1 events · 9 articles · First seen May 15, 2026 · Last active May 16, 2026

Sentiment
80
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
6 80
Tech
Enhertu FDA Approvals for Early Breast Cancer
Trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki), a HER2-directed antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca, has received two new approvals from the United States — Food and Drug Administration. These approvals are for the neoadjuvant…
Impact: Trastuzumab deruxtecan, a HER2-directed antibody drug conjugate, received two new FDA approvals for treating HER2-positive early breast cancer, expanding its market and potential for patient benefit.
May 15, 2026 · 9 articles
Key Actions (2)
100 United States — Food and Drug Administration approved drug Trastuzumab deruxtecanEnhertu FDA Approvals for...
70 Daiichi Sankyo recognized sales Trastuzumab deruxtecanEnhertu FDA Approvals for...
NEWSDESK
Track Trastuzumab deruxtecan live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.